Published in Law and Health Weekly, July 15th, 2006
The patent as maintained protects a production method for herpes simplex virus-1 vaccines including specific oncolytic herpes simplex viruses (cancer-killing HSV) developed by MediGene. The University College of London and the University Court of the University of Glasgow had opposed the patent. The two companies BioVex Ltd., and Crusade Laboratories Ltd., respectively, emerged from these two universities. MediGene had acquired an exclusive license under the patent from the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly